Biogen and Eisai to seek regulatory approval for Alzheimer's medicine
Following a successful late-stage clinical trial in which cognitive decline caused by Alzheimer’s was delayed by 27%, the two companies are ready to head down the market authorization road.
by marketwire, translated by daniel pedersen
Pharmaceutical companies Biogen and Eisai are ready to seek regulatory approval for a new drug targeting Alzheimer’s treatment after a phase III trial provided favorable results, the Financial Times writes.
An HR expert points to increasing competition for skilled workers combined with their pandemic fatigue as factors behind initiatives like Novo Nordisk’s advanced salary talks, Genmab’s extra day off a month, and Bavarian Nordic’s gift of four vacation days.